- Investor's Business Daily•19 hours ago
Tesaro has a commercial advantage over AstraZeneca in their competing ovarian cancer drugs, says RBC.
- GlobeNewswire•3 days ago
WALTHAM, Mass., Oct. 24, 2016-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The Credit Suisse 25 th Annual Healthcare ...
- GlobeNewswire•7 days ago
WALTHAM, Mass., Oct. 20, 2016-- TESARO, Inc. will announce its third-quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.S. financial markets. TESARO’ s senior management ...
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||119.06 x 100|
|Ask||119.30 x 200|
|Day's Range||118.36 - 120.95|
|52wk Range||29.51 - 122.98|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-17.03|
|Avg Vol (3m)||1,129,286|
|Dividend & Yield||N/A (N/A)|